MICHAEL JOHNSON: Open Payments
NPI 1033223995 · FOXWORTH, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$481 in 26 payments from 10 companies in 2025. Trend: 2023 $252 · 2024 $336 · 2025 $481
Food & beverage: $481
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 11 | $211 |
| Novo Nordisk Inc | 4 | $67 |
| AstraZeneca Pharmaceuticals LP | 3 | $56 |
| Lilly USA, LLC | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| ABBVIE INC. | 1 | $19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $6 |
Products named: NURTEC ODT, Ozempic, ELIQUIS, BREZTRI, MOUNJARO, TRINTELLIX, Kerendia, XIFAXAN.
Industry payments across MS — which companies pay providers there.
